Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Chronic Heart Failure

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 124 articles:
HTML format
Text format



Single Articles


    July 2018
  1. DAUBERT MA, Whellan DJ, Woehrle H, Tasissa G, et al
    Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial.
    Am Heart J. 2018;201:40-48.
    PubMed     Text format     Abstract available


  2. UPADHYA B, Brubaker PH, Morgan TM, Eggebeen JD, et al
    The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial.
    Am Heart J. 2018;201:164-167.
    PubMed     Text format     Abstract available


    June 2018
  3. AHMAD FS, French B, Bowles KH, Sevilla-Cazes J, et al
    Incorporating patient-centered factors into heart failure readmission risk prediction: A mixed-methods study.
    Am Heart J. 2018;200:75-82.
    PubMed     Text format     Abstract available


  4. LUO N, Ballew NG, O'Brien EC, Greiner MA, et al
    Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.
    Am Heart J. 2018;200:134-140.
    PubMed     Text format     Abstract available


  5. JALNAPURKAR S, Zhao X, Heidenreich PA, Bhatt DL, et al
    A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure.
    Am Heart J. 2018;200:127-133.
    PubMed     Text format     Abstract available


    May 2018
  6. MCALISTER FA, Youngson E, van Diepen S, Ezekowitz JA, et al
    Influence of hospital volume on outcomes for patients with heart failure: Evidence from a Canadian national cohort study.
    Am Heart J. 2018 May 27. pii: S0002-8703(18)30164.
    PubMed     Text format     Abstract available


  7. SHAKIR M, Wasfy JH
    Heart failure and readmissions: Research in the public eye.
    Am Heart J. 2018;203:1-3.
    PubMed     Text format    


  8. WAGNER J, Agostoni P, Arena R, Belardinelli R, et al
    The Role of Gas Exchange Variables in Cardiopulmonary Exercise Testing for Risk Stratification and Management of Heart Failure with Reduced Ejection Fraction.
    Am Heart J. 2018;202:116-126.
    PubMed     Text format     Abstract available


  9. CAINZOS-ACHIRICA M, Rebordosa C, Vela E, Cleries M, et al
    Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases.
    Am Heart J. 2018;202:76-83.
    PubMed     Text format     Abstract available


  10. LUK A, Groarke JD, Desai AS, Mahmood SS, et al
    First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization.
    Am Heart J. 2018 May 19. pii: S0002-8703(18)30152.
    PubMed     Text format     Abstract available


  11. AMBROSY AP, Bhatt AS, Stebbins AL, Wruck LM, et al
    Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) ran
    Am Heart J. 2018;199:97-104.
    PubMed     Text format     Abstract available


  12. VAN SPALL HGC, Lee SF, Xie F, Ko DT, et al
    Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial.
    Am Heart J. 2018;199:75-82.
    PubMed     Text format     Abstract available


  13. PICCINI JP, Connolly SJ, Abraham WT, Healey JS, et al
    A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
    Am Heart J. 2018;199:51-58.
    PubMed     Text format     Abstract available


  14. AMBROSY AP, Velazquez EJ
    Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means.
    Am Heart J. 2018;199:176-177.
    PubMed     Text format    


  15. JANUZZI JL, Butler J, Fombu E, Maisel A, et al
    Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
    Am Heart J. 2018;199:130-136.
    PubMed     Text format     Abstract available


  16. VETROVEC GW, Anderson M, Schreiber T, Popma J, et al
    The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure.
    Am Heart J. 2018;199:115-121.
    PubMed     Text format     Abstract available


  17. AJAM T, Ajam S, Devaraj S, Mohammed K, et al
    Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction.
    Am Heart J. 2018;199:1-6.
    PubMed     Text format     Abstract available


    April 2018
  18. PENNY WF, Henry TD, Watkins MW, Patel AN, et al
    Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Am Heart J. 2018;201:111-116.
    PubMed     Text format     Abstract available


  19. RAVAL AN, Cook TD, Duckers HJ, Johnston PV, et al
    The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study d
    Am Heart J. 2018;201:141-148.
    PubMed     Text format     Abstract available


  20. VELAZQUEZ EJ, Morrow DA, DeVore AD, Ambrosy AP, et al
    Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    Am Heart J. 2018;198:145-151.
    PubMed     Text format     Abstract available


  21. KHAZANIE P, Hellkamp AS, Fonarow GC, Curtis LH, et al
    Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry.
    Am Heart J. 2018;198:123-128.
    PubMed     Text format     Abstract available


    March 2018
  22. SULLIVAN LT 2ND, Randolph T, Merrill P, Jackson LR 2nd, et al
    Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction.
    Am Heart J. 2018;197:43-52.
    PubMed     Text format     Abstract available


    February 2018
  23. VAN BOVEN N, Battes LC, Akkerhuis KM, Rizopoulos D, et al
    Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study.
    Am Heart J. 2018;196:36-48.
    PubMed     Text format    


    January 2018
  24. MANGLA A, Doukky R, Richardson D, Avery EF, et al
    Design of a bilevel clinical trial targeting adherence in heart failure patients and their providers: The Congestive Heart Failure Adherence Redesign Trial (CHART).
    Am Heart J. 2018;195:139-150.
    PubMed     Text format     Abstract available


    December 2017
  25. DA ROSA PR, Rohde LE, Doebber M, Ribeiro ALP, et al
    Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial.
    Am Heart J. 2017;194:125-131.
    PubMed     Text format     Abstract available


    November 2017
  26. SHADDY R, Canter C, Halnon N, Kochilas L, et al
    Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    Am Heart J. 2017;193:23-34.
    PubMed     Text format     Abstract available


    October 2017
  27. CERBIN LP, Ambrosy AP, Mentz RJ
    Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction.
    Am Heart J. 2017;192:e3.
    PubMed     Text format    


  28. TAYLOR R, Dalal H, Davies R, Doherty P, et al
    Cardiac rehabilitation in heart failure with reduced ejection fraction: A "should take it and not leave it" intervention.
    Am Heart J. 2017;192:e1-e2.
    PubMed     Text format    


  29. GAGGIN HK, Chen-Tournoux AA, Christenson RH, Doros G, et al
    Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department.
    Am Heart J. 2017;192:26-37.
    PubMed     Text format     Abstract available


  30. ADIR Y, Guazzi M, Offer A, Temporelli PL, et al
    Pulmonary hemodynamics in heart failure patients with reduced or preserved ejection fraction and pulmonary hypertension: Similarities and disparities.
    Am Heart J. 2017;192:120-127.
    PubMed     Text format     Abstract available


    September 2017
  31. SHERWOOD A, Hill LK, Blumenthal JA, Adams KF Jr, et al
    Blood pressure reactivity to psychological stress is associated with clinical outcomes in patients with heart failure.
    Am Heart J. 2017;191:82-90.
    PubMed     Text format     Abstract available


  32. LUO N, Teng TK, Tay WT, Anand IS, et al
    Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure.
    Am Heart J. 2017;191:75-81.
    PubMed     Text format     Abstract available


  33. FRIEDMAN DJ, Al-Khatib SM, Zeitler EP, Han J, et al
    New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Am Heart J. 2017;191:21-29.
    PubMed     Text format     Abstract available


    August 2017
  34. AUSTIN CO, Landolfo K, Parikh PP, Patel PC, et al
    Retained cardiac implantable electronic device fragments are not associated with magnetic resonance imaging safety issues, morbidity, or mortality after orthotopic heart transplant.
    Am Heart J. 2017;190:46-53.
    PubMed     Text format     Abstract available


  35. GIMPELEWICZ C, Metra M, Cleland JGF, Szecsody P, et al
    Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial.
    Am Heart J. 2017;190:113-122.
    PubMed     Text format     Abstract available


    July 2017
  36. RANDOLPH TC, Hellkamp AS, Zeitler EP, Fonarow GC, et al
    Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes.
    Am Heart J. 2017;189:48-58.
    PubMed     Text format     Abstract available


  37. HARIKRISHNAN S, Sanjay G, Agarwal A, Kumar NP, et al
    One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: Data from the Trivandrum Heart Failure Registry in Kerala, India.
    Am Heart J. 2017;189:193-199.
    PubMed     Text format     Abstract available


  38. DEVORE AD, Thomas L, Albert NM, Butler J, et al
    Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry.
    Am Heart J. 2017;189:177-183.
    PubMed     Text format     Abstract available


  39. CUNNINGHAM JW, Nathan AS, Rhodes J, Shafer K, et al
    Decline in peak oxygen consumption over time predicts death or transplantation in adults with a Fontan circulation.
    Am Heart J. 2017;189:184-192.
    PubMed     Text format     Abstract available


    June 2017
  40. TER MAATEN JM, Maggioni AP, Latini R, Masson S, et al
    Clinical and prognostic value of spot urinary creatinine in chronic heart failure-An analysis from GISSI-HF.
    Am Heart J. 2017;188:189-195.
    PubMed     Text format     Abstract available


  41. BRISCO-BACIK MA
    Prognostication on the spot! The evolving importance of urinary creatinine in heart failure.
    Am Heart J. 2017;188:186-188.
    PubMed     Text format    


  42. GOLDBERG SL, Meredith I, Marwick T, Haluska BA, et al
    A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failure-Trial design of the REDUCE FMR study.
    Am Heart J. 2017;188:167-174.
    PubMed     Text format     Abstract available


  43. RASLAN IR, Brown P, Westerhout CM, Ezekowitz JA, et al
    Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score.
    Am Heart J. 2017;188:127-135.
    PubMed     Text format     Abstract available


  44. VUKADINOVIC D, Lavall D, Vukadinovic AN, Pitt B, et al
    True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis.
    Am Heart J. 2017;188:99-108.
    PubMed     Text format     Abstract available


  45. MOGENSEN UM, Kober L, Kristensen SL, Jhund PS, et al
    The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
    Am Heart J. 2017;188:35-41.
    PubMed     Text format     Abstract available


  46. JOHANSEN ND, Biering-Sorensen T, Jensen JS, Mogelvang R, et al
    Diastolic dysfunction revisited: A new, feasible, and unambiguous echocardiographic classification predicts major cardiovascular events.
    Am Heart J. 2017;188:136-146.
    PubMed     Text format     Abstract available


    May 2017
  47. PANG PS, Teerlink JR, Boer-Martins L, Gimpelewicz C, et al
    Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial.
    Am Heart J. 2017;187:62-69.
    PubMed     Text format     Abstract available


    April 2017
  48. BAEZA-TRINIDAD R, Mosquera-Lozano JD
    Bendopnea: The next prognostic marker of advanced heart failure?
    Am Heart J. 2017;186:e1.
    PubMed     Text format    


  49. ECHOUFFO-TCHEUGUI JB, Bishu KG, Fonarow GC, Egede LE, et al
    Trends in health care expenditure among US adults with heart failure: The Medical Expenditure Panel Survey 2002-2011.
    Am Heart J. 2017;186:63-72.
    PubMed     Text format     Abstract available


  50. AMBROSY AP, Cerbin LP, DeVore AD, Greene SJ, et al
    Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial.
    Am Heart J. 2017;186:130-138.
    PubMed     Text format     Abstract available


  51. FLINT K
    Cardiac rehabilitation in heart failure with reduced ejection fraction: A "take it or leave it" intervention.
    Am Heart J. 2017;186:127-129.
    PubMed     Text format    


    March 2017
  52. KUPSKY DF, Ahmed AM, Sakr S, Qureshi WT, et al
    Cardiorespiratory fitness and incident heart failure: The Henry Ford ExercIse Testing (FIT) Project.
    Am Heart J. 2017;185:35-42.
    PubMed     Text format     Abstract available


  53. REEVES GR, Whellan DJ, Duncan P, O'Connor CM, et al
    Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale.
    Am Heart J. 2017;185:130-139.
    PubMed     Text format     Abstract available


  54. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    PubMed     Text format     Abstract available


  55. ROBINSON VM, Bharucha DB, Mahaffey KW, Dorian P, et al
    Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
    Am Heart J. 2017;185:43-51.
    PubMed     Text format     Abstract available


  56. BARRIOS D, Morillo R, Lobo JL, Nieto R, et al
    Assessment of right ventricular function in acute pulmonary embolism.
    Am Heart J. 2017;185:123-129.
    PubMed     Text format     Abstract available


  57. HORNE BD, Budge D, Masica AL, Savitz LA, et al
    Early inpatient calculation of laboratory-based 30-day readmission risk scores empowers clinical risk modification during index hospitalization.
    Am Heart J. 2017;185:101-109.
    PubMed     Text format     Abstract available


  58. RICCI F, Mele D, Bianco F, Bucciarelli V, et al
    Right heart-pulmonary circulation unit and cardiac resynchronization therapy.
    Am Heart J. 2017;185:1-16.
    PubMed     Text format     Abstract available


    February 2017
  59. KHAN H, Jaffar N, Rauramaa R, Kurl S, et al
    Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study.
    Am Heart J. 2017;184:55-61.
    PubMed     Text format     Abstract available


    January 2017
  60. VERMA AK, Schulte PJ, Bittner V, Keteyian SJ, et al
    Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes.
    Am Heart J. 2017;183:54-61.
    PubMed     Text format     Abstract available


  61. COX ZL, Lewis CM, Lai P, Lenihan DJ, et al
    Validation of an automated electronic algorithm and "dashboard" to identify and characterize decompensated heart failure admissions across a medical center.
    Am Heart J. 2017;183:40-48.
    PubMed     Text format     Abstract available


  62. NAGARAJAN V, Hernandez AV, Cauthen CA, Starling RC, et al
    Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure.
    Am Heart J. 2017;183:35-39.
    PubMed     Text format     Abstract available


  63. STEINHAUS DA, Mostofsky E, Levitan EB, Dorans KS, et al
    Chocolate intake and incidence of heart failure: Findings from the Cohort of Swedish Men.
    Am Heart J. 2017;183:18-23.
    PubMed     Text format     Abstract available


  64. THIBODEAU JT, Jenny BE, Maduka JO, Divanji PH, et al
    Bendopnea and risk of adverse clinical outcomes in ambulatory patients with systolic heart failure.
    Am Heart J. 2017;183:102-107.
    PubMed     Text format     Abstract available


    December 2016
  65. ECHOUFFO-TCHEUGUI JB, Xu H, DeVore AD, Schulte PJ, et al
    Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry.
    Am Heart J. 2016;182:9-20.
    PubMed     Text format     Abstract available


  66. SPITZER E, Van Mieghem NM, Pibarot P, Hahn RT, et al
    Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial.
    Am Heart J. 2016;182:80-88.
    PubMed     Text format     Abstract available


    November 2016
  67. LEE DS, Lee JS, Schull MJ, Grimshaw JM, et al
    Design and rationale for the Acute Congestive Heart Failure Urgent Care Evaluation: The ACUTE Study.
    Am Heart J. 2016;181:60-65.
    PubMed     Text format     Abstract available


  68. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    PubMed     Text format     Abstract available


    September 2016
  69. THUNE JJ, Pehrson S, Nielsen JC, Haarbo J, et al
    Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH).
    Am Heart J. 2016;179:136-41.
    PubMed     Text format     Abstract available


  70. GILOTRA NA, Bennett MK, Shpigel A, Ahmed HM, et al
    Outcomes and predictors of recovery in acute-onset cardiomyopathy: A single-center experience of patients undergoing endomyocardial biopsy for new heart failure.
    Am Heart J. 2016;179:116-26.
    PubMed     Text format     Abstract available


  71. SHREIBATI JB, Sheng S, Fonarow GC, DeVore AD, et al
    Heart failure medications prescribed at discharge for patients with left ventricular assist devices.
    Am Heart J. 2016;179:99-106.
    PubMed     Text format     Abstract available


  72. YAZDAN-ASHOORI P, Lee SF, Ibrahim Q, Van Spall HG, et al
    Utility of the LACE index at the bedside in predicting 30-day readmission or death in patients hospitalized with heart failure.
    Am Heart J. 2016;179:51-8.
    PubMed     Text format     Abstract available


  73. MCNEELY C, Markwell S, Vassileva CM
    Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012.
    Am Heart J. 2016;179:195-203.
    PubMed     Text format     Abstract available


  74. BUCK J, Kaboli P, Gage BF, Cram P, et al
    Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
    Am Heart J. 2016;179:186-91.
    PubMed     Text format     Abstract available


  75. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Am Heart J. 2016;179:175-83.
    PubMed     Text format     Abstract available


  76. SHAH R, Hellkamp A, Lokhnygina Y, Becker RC, et al
    Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Am Heart J. 2016;179:77-86.
    PubMed     Text format     Abstract available


    August 2016
  77. DEVORE AD, Greiner MA, Sharma PP, Qualls LG, et al
    Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE).
    Am Heart J. 2016;178:198-205.
    PubMed     Text format     Abstract available


  78. ALLEN LA, McIlvennan CK
    Predicting in-hospital worsening heart failure at time of admission, but do we really need another heart failure risk model?
    Am Heart J. 2016;178:188-9.
    PubMed     Text format    


  79. MALEBRANCHE R, Tabou Moyo C, Morisset PH, Raphael NA, et al
    Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti.
    Am Heart J. 2016;178:151-60.
    PubMed     Text format     Abstract available


  80. PAINE NJ, Hinderliter AL, Blumenthal JA, Adams KF Jr, et al
    Reactive hyperemia is associated with adverse clinical outcomes in heart failure.
    Am Heart J. 2016;178:108-14.
    PubMed     Text format     Abstract available


  81. FROHLICH H, Nelges C, Tager T, Schwenger V, et al
    Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Am Heart J. 2016;178:28-36.
    PubMed     Text format     Abstract available


    July 2016
  82. PEGUERO JG, Lo Presti S, Issa O, Podesta C, et al
    Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R2CHADS2.
    Am Heart J. 2016;177:153-9.
    PubMed     Text format     Abstract available


  83. KIM EJ, Yin X, Fontes JD, Magnani JW, et al
    Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study).
    Am Heart J. 2016;177:138-44.
    PubMed     Text format     Abstract available


  84. BAKKESTROM R, Larsen LA, Moller JE, Videbaek L, et al
    Mitral valve regurgitation in twins: Concordance and survival.
    Am Heart J. 2016;177:51-7.
    PubMed     Text format     Abstract available


    May 2016
  85. PAPADIMITRIOU L, Smith-Jones PM, Sarwar CM, Marti CN, et al
    Utility of positron emission tomography for drug development for heart failure.
    Am Heart J. 2016;175:142-52.
    PubMed     Text format     Abstract available


    April 2016
  86. SHAFIQ A, Brawner CA, Aldred HA, Lewis B, et al
    Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry Ford HospITal CardioPulmonary EXercise Testing (FIT-CPX) project.
    Am Heart J. 2016;174:167-72.
    PubMed     Text format     Abstract available


  87. GUAZZI M
    Cardiopulmonary exercise testing in heart failure preserved ejection fraction: Time to expand the paradigm in the prognostic algorithm.
    Am Heart J. 2016;174:164-6.
    PubMed     Text format    


  88. AXON RN, Gebregziabher M, Everett CJ, Heidenreich P, et al
    Dual health care system use is associated with higher rates of hospitalization and hospital readmission among veterans with heart failure.
    Am Heart J. 2016;174:157-63.
    PubMed     Text format     Abstract available


  89. DESAI NR
    Toward evidence-based health care delivery reform.
    Am Heart J. 2016;174:154-6.
    PubMed     Text format    


    March 2016
  90. DEVORE AD, Mi X, Mentz RJ, Fonarow GC, et al
    Discharge heart rate and beta-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry.
    Am Heart J. 2016;173:172-8.
    PubMed     Text format     Abstract available


  91. COLE RT
    Making a case for ivabradine: Should we SHIFT our focus to OPTIMIZE outcomes?
    Am Heart J. 2016;173:170-1.
    PubMed     Text format    


    February 2016
  92. ABOUEZZEDDINE OF, Lala A, Khazanie PP, Shah R, et al
    Evaluation of a provocative dyspnea severity score in acute heart failure.
    Am Heart J. 2016;172:34-41.
    PubMed     Text format     Abstract available


    January 2016
  93. SHIRAISHI Y, Kohsaka S, Abe T, Mizuno A, et al
    Validation of the Get With The Guideline-Heart Failure risk score in Japanese patients and the potential improvement of its discrimination ability by the inclusion of B-type natriuretic peptide level.
    Am Heart J. 2016;171:33-9.
    PubMed     Text format     Abstract available


    December 2015
  94. COOPER LB, Hammill BG, Sharma PP, DeVore AD, et al
    Differences in health care use and outcomes by the timing of in-hospital worsening heart failure.
    Am Heart J. 2015;170:1124-32.
    PubMed     Text format     Abstract available


  95. VAKIL KP, Roukoz H, Tung R, Levy WC, et al
    Mortality prediction using a modified Seattle Heart Failure Model may improve patient selection for ventricular tachycardia ablation.
    Am Heart J. 2015;170:1099-104.
    PubMed     Text format     Abstract available


    November 2015
  96. FISCHER C, Steyerberg EW, Fonarow GC, Ganiats TG, et al
    A systematic review and meta-analysis on the association between quality of hospital care and readmission rates in patients with heart failure.
    Am Heart J. 2015;170:1005-1017.
    PubMed     Text format     Abstract available


  97. GILSTRAP LG, Joynt KE
    Both processes and readmissions matter for heart failure: How can we align them?
    Am Heart J. 2015;170:968-70.
    PubMed     Text format    


  98. LAZO M, Halushka MK, Shen L, Maruthur N, et al
    Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study.
    Am Heart J. 2015;170:961-7.
    PubMed     Text format     Abstract available


  99. REED SD, Neilson MP, Gardner M, Li Y, et al
    Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.
    Am Heart J. 2015;170:951-60.
    PubMed     Text format     Abstract available


  100. SNIPELISKY D, Stulak JM, Schettle SD, Sharma S, et al
    Psychosocial characteristics and outcomes in patients with left ventricular assist device implanted as destination therapy.
    Am Heart J. 2015;170:887-94.
    PubMed     Text format     Abstract available


    October 2015
  101. DOKAINISH H, Teo K, Zhu J, Roy A, et al
    Heart failure in low- and middle-income countries: Background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF).
    Am Heart J. 2015;170:627-634.
    PubMed     Text format     Abstract available


    September 2015
  102. CHAUHAN V, Dev S, Pham M, Lin S, et al
    Facility variation and predictors of serum potassium monitoring after initiation of a mineralocorticoid receptor antagonist in patients with heart failure.
    Am Heart J. 2015;170:543-9.
    PubMed     Text format     Abstract available


  103. SALAH K, Pinto YM, Eurlings LW, Metra M, et al
    Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: An individual patient data analysis.
    Am Heart J. 2015;170:531-542.
    PubMed     Text format     Abstract available


  104. LUM HD, Jones J, Lahoff D, Allen LA, et al
    Unique challenges of hospice for patients with heart failure: A qualitative study of hospice clinicians.
    Am Heart J. 2015;170:524-530.
    PubMed     Text format     Abstract available


  105. COSTANZO MR, Negoianu D, Fonarow GC, Jaski BE, et al
    Rationale and design of the Aquapheresis Versus Intravenous Diuretics and Hospitalization for Heart Failure (AVOID-HF) trial.
    Am Heart J. 2015;170:471-82.
    PubMed     Text format     Abstract available


    August 2015
  106. TER MAATEN JM, Dunning AM, Valente MA, Damman K, et al
    Diuretic response in acute heart failure-an analysis from ASCEND-HF.
    Am Heart J. 2015;170:313-321.
    PubMed     Text format     Abstract available


  107. CORRALES-MEDINA VF, Taljaard M, Yende S, Kronmal R, et al
    Intermediate and long-term risk of new-onset heart failure after hospitalization for pneumonia in elderly adults.
    Am Heart J. 2015;170:306-312.
    PubMed     Text format     Abstract available


  108. KELLY JP, Mentz RJ, Hasselblad V, Ezekowitz JA, et al
    Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF).
    Am Heart J. 2015;170:298-305.
    PubMed     Text format     Abstract available


  109. KHAZANIE P, Heizer GM, Hasselblad V, Armstrong PW, et al
    Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models.
    Am Heart J. 2015;170:290-297.
    PubMed     Text format     Abstract available


  110. RUSSO AM, Daugherty SL, Masoudi FA, Wang Y, et al
    Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR).
    Am Heart J. 2015;170:330-8.
    PubMed     Text format     Abstract available


  111. HEIDENREICH PA, Tsai V, Curtis J, Wang Y, et al
    A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement.
    Am Heart J. 2015;170:281-289.
    PubMed     Text format     Abstract available


  112. ZEITLER EP, Al-Khatib SM
    Primary prevention implantable cardioverter defibrillators in women: More questions than answers.
    Am Heart J. 2015;170:197-9.
    PubMed     Text format    


    July 2015
  113. CAPODANNO D, Adamo M, Barbanti M, Giannini C, et al
    Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair.
    Am Heart J. 2015;170:187-95.
    PubMed     Text format     Abstract available


  114. CHRISTODOULIDIS G, Yu J, Kini A, Dangas GD, et al
    Gender-specific outcomes after balloon aortic valvuloplasty: Inhospital and long-term outcomes.
    Am Heart J. 2015;170:180-6.
    PubMed     Text format     Abstract available


  115. DAMLUJI AA, Al-Damluji MS, Marzouka GR, Coffey JO, et al
    New-onset versus prior history of atrial fibrillation: Outcomes from the AFFIRM trial.
    Am Heart J. 2015;170:156-163.
    PubMed     Text format     Abstract available


  116. POKORNEY SD, Simon DN, Thomas L, Fonarow GC, et al
    Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
    Am Heart J. 2015;170:141-148.
    PubMed     Text format     Abstract available


  117. OKRAINEC K, Bell CM, Hollands S, Booth GL, et al
    Risk of cardiovascular events and mortality among a population-based cohort of immigrants and long-term residents with diabetes: Are all immigrants healthier and if so, for how long?
    Am Heart J. 2015;170:123-32.
    PubMed     Text format     Abstract available


    June 2015
  118. KIM KH, Kim HK, Hwang IC, Cho HJ, et al
    PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
    Am Heart J. 2015;169:813-822.
    PubMed     Text format     Abstract available


  119. GRODIN JL, Drazner MH, Dupont M, Mullens W, et al
    A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure.
    Am Heart J. 2015;169:806-12.
    PubMed     Text format     Abstract available


    May 2015
  120. OH J, Kang SM, Song MK, Hong N, et al
    Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry.
    Am Heart J. 2015;169:713-720.
    PubMed     Text format     Abstract available


  121. SCHROTEN NF, Damman K, Hemmelder MH, Voors AA, et al
    Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Hea
    Am Heart J. 2015;169:693-701.
    PubMed     Text format     Abstract available


  122. RUSSO C, Jin Z, Homma S, Rundek T, et al
    Race-ethnic differences in subclinical left ventricular systolic dysfunction by global longitudinal strain: A community-based cohort study.
    Am Heart J. 2015;169:721-6.
    PubMed     Text format     Abstract available


  123. HAHN JY, Yu CW, Park HS, Song YB, et al
    Long-term effects of ischemic postconditioning on clinical outcomes: 1-year follow-up of the POST randomized trial.
    Am Heart J. 2015;169:639-46.
    PubMed     Text format     Abstract available


  124. HOFSTEN DE, Kelbaek H, Helqvist S, Klovgaard L, et al
    The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: Ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularization versus treat
    Am Heart J. 2015;169:613-21.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: